US FDA approves Evolus' anti-wrinkle gels
Feb 13 (Reuters) - Evolus EOLS.O said on Thursday the
U.S. Food and Drug Administration has approved its two new
anti-wrinkle injectable gels, expanding the company's product
portfolio beyond its cosmetic injection Jeuveau.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi
Majumdar)
((Christy.Santhosh@thomsonreuters.com;))
Recent news on Evolus
See all newsEvolus Inc reports results for the quarter ended June 30 - Earnings Summary
Evolus Q2 revenue rises 21%, lifts 2026 outlook
Brief: Evolus Q2 Product Revenue USD 83.35 Million
Evolus Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Evolus Announces Commercial Launch Of Estyme® Injectable Hyaluronic Acid Gels In Europe